- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine
The Indian Patent Office has repudiated Germany’s Boehringer Ingelheim patent on its key HIV drug- Nevirapine, Patent Application Number: 4724/DELNP/2009 entitled “Extended-release formulation of Nevirapine”, for a version sold as Viramune XR (extended-release), once again forestalling attempts by Big Pharma for “exclusivity” extension on their patented drugs to reportedly block entry of reasonably priced generics. … Continue reading Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine
Read more »Revocation of Valganciclovir patent by Controller of Patents, Chennai
August 1, 2015 - 9:46 am
Categories:
IPAB
IPAB Decisions
News & Updates
Patent Opposition
Patents
pharma
Pharma/Biotech Patent Litigations
Section 3(D)
0 Comments Recently in a matter remanded from IPAB to Controller of Patents, Chennai, a decision of revoking Roche’s patent IN207232 for Valganciclovir was delivered after hearing both the parties. The subject patent was granted on January, 2009 followed which post grant oppositions were separately filed by CIPLA, Matrix, Ranbaxy and Bakul Pharma along with two NGOs … Continue reading Revocation of Valganciclovir patent by Controller of Patents, Chennai
Read more »Section 3(D) of Indian Patent Act Strikes Again
July 27, 2015 - 5:24 am
Categories:
India
News & Updates
patent infringement
Patent Opposition
Patents
pharma
Section 3(D)
0 Comments India revoked yet another drug patent granted to a German MNC, Boehringer Ingelheim, for its respiratory drug, Spiriva (crystalline tiotropium bromide monohydrate) at a time when the US is putting pressure on the Indian government for not providing adequate patent protection to multinational drug companies. In its decision, the patent office held that Boehringer failed … Continue reading Section 3(D) of Indian Patent Act Strikes Again
Read more »Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR
February 23, 2015 - 7:46 am
Categories:
IP Practice in India
News & Updates
Patents
pharma
Section 3(D)
0 Comments Recently, the Delhi high court dated 30th January 2015 set aside an order of the Deputy Controller of Patents and Designs. The impugned order rejected a patent to US drugmaker Gilead for its hepatitis C drug “Sovaldi” on dated 13th January 2015. M/S GILEAD PHARMASSET, INC, USA, filed a patent application on 30/05/2003 in the … Continue reading Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR
Read more »